{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T10:35:27Z","timestamp":1777113327749,"version":"3.51.4"},"reference-count":31,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T00:00:00Z","timestamp":1763769600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Taiwanese Journal of Obstetrics and Gynecology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.tjog.2025.04.024","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T19:47:33Z","timestamp":1769629653000},"page":"75-80","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Impact of niraparib on reducing the platelet count in patients with ovarian cancer"],"prefix":"10.1016","volume":"65","author":[{"given":"Mika","family":"Mizuno","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mai","family":"Nakazono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mika","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shintaro","family":"Yanazume","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichi","family":"Togami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.tjog.2025.04.024_bib1","series-title":"GLOBOCAN 2020: estimated cancer incidence, mortality and prevalence worldwide in 2020","year":"2020"},{"key":"10.1016\/j.tjog.2025.04.024_bib2","series-title":"Cancer statistics in Japan \u2013 2021","year":"2020"},{"issue":"7353","key":"10.1016\/j.tjog.2025.04.024_bib3","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","author":"Cancer Genome Atlas Research","year":"2011","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.tjog.2025.04.024_bib4","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1186\/s12885-021-08863-9","article-title":"Homologous recombination proficiency in ovarian and breast cancer patients","volume":"21","author":"Creeden","year":"2021","journal-title":"BMC Cancer"},{"issue":"20","key":"10.1016\/j.tjog.2025.04.024_bib5","doi-asserted-by":"crossref","first-page":"5681","DOI":"10.1158\/1078-0432.CCR-21-0981","article-title":"Comparative assessment of diagnostic homologous recombination deficiency-associated mutational signatures in ovarian cancer","volume":"27","author":"Sztupinszki","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"19","key":"10.1016\/j.tjog.2025.04.024_bib6","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14194621","article-title":"Targeting homologous recombination deficiency in ovarian cancer with PARP inhibitors: synthetic lethal strategies that impact overall survival","volume":"14","author":"Xie","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"12","key":"10.1016\/j.tjog.2025.04.024_bib7","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1002\/cncr.21536","article-title":"BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases","volume":"104","author":"Pal","year":"2005","journal-title":"Cancer"},{"issue":"23","key":"10.1016\/j.tjog.2025.04.024_bib8","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1093\/jnci\/djj465","article-title":"Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada","volume":"98","author":"Risch","year":"2006","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"10.1016\/j.tjog.2025.04.024_bib9","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1001\/jamaoncol.2015.5495","article-title":"Inherited mutations in women with ovarian carcinoma","volume":"2","author":"Norquist","year":"2016","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.tjog.2025.04.024_bib10","doi-asserted-by":"crossref","first-page":"334 e1","DOI":"10.1016\/j.ajog.2017.05.036","article-title":"BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study","volume":"217","author":"Petrillo","year":"2017","journal-title":"Am J Obstet Gynecol"},{"issue":"5","key":"10.1016\/j.tjog.2025.04.024_bib11","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/modpathol.2011.211","article-title":"BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma","volume":"25","author":"McAlpine","year":"2012","journal-title":"Mod Pathol"},{"issue":"22","key":"10.1016\/j.tjog.2025.04.024_bib12","doi-asserted-by":"crossref","first-page":"3570","DOI":"10.1200\/JCO.2009.27.2997","article-title":"Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer","volume":"28","author":"Hennessy","year":"2010","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1016\/j.tjog.2025.04.024_bib13","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer","volume":"381","author":"Gonzalez-Martin","year":"2019","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.tjog.2025.04.024_bib14","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1177\/1060028020912749","article-title":"Niraparib for the treatment of recurrent Epithelial ovarian, Fallopian tube, or primary peritoneal cancer","volume":"54","author":"Kerliu","year":"2020","journal-title":"Ann Pharmacother"},{"issue":"2","key":"10.1016\/j.tjog.2025.04.024_bib15","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.3802\/jgo.2021.32.e21","article-title":"Phase 2 single-arm study on the safety of maintenance niraparib in Japanese patients with platinum-sensitive relapsed ovarian cancer","volume":"32","author":"Takehara","year":"2021","journal-title":"J Gynecol Oncol"},{"issue":"9","key":"10.1016\/j.tjog.2025.04.024_bib16","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Pujade-Lauraine","year":"2017","journal-title":"Lancet Oncol"},{"issue":"22","key":"10.1016\/j.tjog.2025.04.024_bib17","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.tjog.2025.04.024_bib18","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/S1470-2045(19)30029-4","article-title":"Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial","volume":"20","author":"Moore","year":"2019","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.tjog.2025.04.024_bib19","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.annonc.2020.12.018","article-title":"Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): a randomized, double-blind, placebo-controlled phase III trial(\u2606)","volume":"32","author":"Wu","year":"2021","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.tjog.2025.04.024_bib20","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1001\/jamaoncol.2023.2283","article-title":"Treatment with niraparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer: a phase 3 randomized clinical trial","volume":"9","author":"Li","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.tjog.2025.04.024_bib21","series-title":"Common terminology criteria for adverse events (CTCAE) v5.0","author":"Institute","year":"2018"},{"issue":"6","key":"10.1016\/j.tjog.2025.04.024_bib22","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1136\/ijgc-2022-004079","article-title":"Safety and management of niraparib monotherapy in ovarian cancer clinical trials","volume":"33","author":"Monk","year":"2023","journal-title":"Int J Gynecol Cancer"},{"issue":"12","key":"10.1016\/j.tjog.2025.04.024_bib23","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1002\/cncr.34706","article-title":"Prospective evaluation of the tolerability and efficacy of niraparib dosing based on baseline body weight and platelet count: results from the PRIMA\/ENGOT-OV26\/GOG-3012 trial","volume":"129","author":"Mirza","year":"2023","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.tjog.2025.04.024_bib24","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3390\/curroncol29010029","article-title":"Safety profile of Niraparib as maintenance therapy for ovarian cancer: a systematic review and meta-analysis","volume":"29","author":"Pagkali","year":"2022","journal-title":"Curr Oncol"},{"key":"10.1016\/j.tjog.2025.04.024_bib25","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ygyno.2023.11.037","article-title":"Comparison of survival outcomes between olaparib and niraparib maintenance therapy in BRCA-mutated, newly diagnosed advanced ovarian cancer","volume":"181","author":"Kim","year":"2024","journal-title":"Gynecol Oncol"},{"issue":"6","key":"10.1016\/j.tjog.2025.04.024_bib26","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s11523-023-00999-x","article-title":"Efficacy and safety of Niraparib as first-line maintenance treatment for patients with advanced ovarian cancer: Real-world data from a multicenter study in China","volume":"18","author":"Zhao","year":"2023","journal-title":"Target Oncol"},{"issue":"3","key":"10.1016\/j.tjog.2025.04.024_bib27","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.ygyno.2018.12.009","article-title":"Efficacy and safety of niraparib as maintenance treatment in older patients (>\/= 70 years) with recurrent ovarian cancer: results from the ENGOT-OV16\/NOVA trial","volume":"152","author":"Fabbro","year":"2019","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.tjog.2025.04.024_bib28","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S1470-2045(14)71135-0","article-title":"Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial","volume":"16","author":"Oza","year":"2015","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.tjog.2025.04.024_bib29","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ygyno.2017.10.007","article-title":"Tolerance and toxicity of the PARP inhibitor olaparib in older women with epithelial ovarian cancer","volume":"147","author":"Dockery","year":"2017","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.tjog.2025.04.024_bib30","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s10147-022-02258-x","article-title":"Veliparib with frontline chemotherapy and as maintenance in Japanese women with ovarian cancer: a subanalysis of efficacy, safety, and antiemetic use in the phase 3 VELIA trial","volume":"28","author":"Mizuno","year":"2023","journal-title":"Int J Clin Oncol"},{"issue":"25","key":"10.1016\/j.tjog.2025.04.024_bib31","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1056\/NEJMoa1909707","article-title":"Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer","volume":"381","author":"Coleman","year":"2019","journal-title":"N Engl J Med"}],"container-title":["Taiwanese Journal of Obstetrics and Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1028455925003109?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1028455925003109?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T19:48:23Z","timestamp":1769629703000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1028455925003109"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1028455925003109"],"URL":"https:\/\/doi.org\/10.1016\/j.tjog.2025.04.024","relation":{},"ISSN":["1028-4559"],"issn-type":[{"value":"1028-4559","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of niraparib on reducing the platelet count in patients with ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"Taiwanese Journal of Obstetrics and Gynecology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tjog.2025.04.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Taiwan Association of Obstetrics & Gynecology. Publishing services by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}